Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment

The mechanistic target of rapamycin (mTOR) is hyperactivated in many types of cancer, rendering it a compelling drug target; however, the impact of mTOR inhibition on metabolic reprogramming in cancer is incompletely understood. Here, by integrating metabolic and functional studies in glioblastoma m...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Clin Invest
Hauptverfasser: Tanaka, Kazuhiro, Sasayama, Takashi, Irino, Yasuhiro, Takata, Kumi, Nagashima, Hiroaki, Satoh, Naoko, Kyotani, Katsusuke, Mizowaki, Takashi, Imahori, Taichiro, Ejima, Yasuo, Masui, Kenta, Gini, Beatrice, Yang, Huijun, Hosoda, Kohkichi, Sasaki, Ryohei, Mischel, Paul S., Kohmura, Eiji
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society for Clinical Investigation 2015
Schlagworte:
Research Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4396477/
https://ncbi.nlm.nih.gov/pubmed/25798620
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI78239
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge